Patents by Inventor Mark Bruner

Mark Bruner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIV vaccine formulation
    Patent number: 11603389
    Abstract: Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods for storing the immunogenic compositions.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: March 14, 2023
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Thierry-Thien Nguyen, Mark Bruner
  • HIV Vaccine Formulation
    Publication number: 20210179670
    Abstract: Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods for storing the immunogenic compositions.
    Type: Application
    Filed: February 9, 2021
    Publication date: June 17, 2021
    Inventors: Thierry-Thien Nguyen, Mark Bruner
  • HIV vaccine formulation
    Patent number: 10934328
    Abstract: Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: March 2, 2021
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Thierry-Thien Nguyen, Mark Bruner
  • HIV VACCINE FORMULATION
    Publication number: 20190202870
    Abstract: Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.
    Type: Application
    Filed: March 20, 2019
    Publication date: July 4, 2019
    Inventors: Thierry-Thien NGUYEN, Mark BRUNER
  • HIV vaccine formulation
    Patent number: 10273268
    Abstract: Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: April 30, 2019
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Thierry-Thien Nguyen, Mark Bruner
  • HIV VACCINE FORMULATION
    Publication number: 20170362280
    Abstract: Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.
    Type: Application
    Filed: June 15, 2017
    Publication date: December 21, 2017
    Inventors: Thierry-Thien NGUYEN, Mark BRUNER
  • DNA vaccine formulations
    Patent number: 7927870
    Abstract: This invention relates to novel methods and formulations of nucleic acid pharmaceutical products, specifically formulations of nucleic acid vaccine products and nucleic acid gene therapy products. The formulations of the disclosure stabilize the conformation of DNA pharmaceutical products.
    Type: Grant
    Filed: May 10, 2006
    Date of Patent: April 19, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: David B. Volkin, Robert K. Evans, Mark Bruner
  • DNA vaccine formulations
    Publication number: 20060217341
    Abstract: This invention relates to novel methods and formulations of nucleic acid pharmaceutical products, specifically formulations of nucleic acid vaccine products and nucleic acid gene therapy products. The formulations of the disclosure stabilize the conformation of DNA pharmaceutical products.
    Type: Application
    Filed: May 10, 2006
    Publication date: September 28, 2006
    Inventors: David Volkin, Robert Evans, Mark Bruner
  • DNA vaccine formulations
    Publication number: 20040138165
    Abstract: This invention relates to novel methods and formulations of nucleic acid pharmaceutical products, specifically formulations of nucleic acid vaccine products and nucleic acid gene therapy products. The formulations of the disclosure stabilize the conformation of DNA pharmaceutical products.
    Type: Application
    Filed: October 30, 2003
    Publication date: July 15, 2004
    Applicant: Merck & Co., Inc.
    Inventors: David B. Volkin, Robert K. Evans, Mark Bruner
  • DNA vaccine formulations
    Publication number: 20020156037
    Abstract: This invention relates to novel methods and formulations of nucleic acid pharmaceutical products, specifically formulations of nucleic acid vaccine products and nucleic acid gene therapy products. The formulations of the disclosure stabilize the conformation of DNA pharmaceutical products.
    Type: Application
    Filed: September 7, 2001
    Publication date: October 24, 2002
    Applicant: Merck & Co., Inc.
    Inventors: David B. Volkin, Robert K. Evans, Mark Bruner